Our next-generation chemoproteomic platform reaches beyond the limitations of existing approaches, enabling us to pursue any target class with unprecedented speed and efficiency – a major advance towards systematically drugging the undruggable.
Enabled by our RAPID platform, we’re developing a
pipeline of first and best-in-class therapeutics
addressing high value targets for rare genetic diseases,
immune-mediated diseases and oncology.
Enabled by our RAPID platform, we’re developing a
pipeline of first and best-in-class therapeutics
addressing high value targets for rare genetic diseases,
immune-mediated diseases and oncology.
At Jnana, our highly experienced, innovative and collaborative team is what allows us to pioneer untapped science with incredible potential for patient impact.
This links to an external website. Merus is not responsible for any third party content.